Tumor hyperthermia research progress and application prospect in tumoroids (Review)

Mao,Wei; Li,Wen; Hu,Xuguang

doi:10.3892/mco.2024.2729

Tumor hyperthermia research progress and application prospect in tumoroids (Review)

Authors:
- Wei Mao
- Wen Li
- Xuguang Hu
View Affiliations

Affiliations: Department of General Surgery, Nanchang University Infectious Disease Hospital, Nanchang, Jiangxi 330002, P.R. China, Central Laboratory, Nanchang University Infectious Disease Hospital, Nanchang, Jiangxi 330002, P.R. China, Department of Hepatobiliary Surgery, Organ Transplantation Center, Jiangxi Provincial People's Hospital, Donghu, Nanchang, Jiangxi 330001, P.R. China
Published online on: February 14, 2024 https://doi.org/10.3892/mco.2024.2729
Article Number: 31
Copyright: © Mao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor hyperthermia is the fifth tumor treatment method after surgery, chemotherapy, radiotherapy and biological therapy, and is also one of the important adjuvant treatment methods for tumors. Hyperthermia can not only directly eliminate tumor cells, but also stimulate the antitumor immune response of the body, and improve the sensitivity of tumor tissues to radiotherapy and chemotherapy. An organoid is a tissue‑specific cell cluster formed by 3D culture of various types of cells derived from target organ stem cells, which can reproduce the functions of target organs in vivo. At present, the research models of hepatocellular carcinoma (HCC) in vitro are mainly 2D culture cell line models, and there is no clinical report on tumor hyperthermia using HCC tumoroids. It was hypothesized that this will be a promising research direction.

View Figures

View References

1	Zhao YY, Xu YS and Wu Q: Research progress on tumor hyperthermia. Chin J Radiat Oncol. 30:862–866. 2021.
2	Yi GY, Kim MJ, Kim HI, Park J and Baek SH: Hyperthermia treatment as a promising anti-cancer strategy: Therapeutic targets, perspective mechanisms and synergistic combinations in experimental approaches. Antioxidants (Basel). 11(625)2022.PubMed/NCBI View Article : Google Scholar
3	Qi BN, Wang XP and Wang XN: The effect and mechanism of hyperthermia on immune cells. Modern Oncol. 26:2635–2639. 2018.
4	Basile A, Biziato D, Sherbet GV, Comi P and Cajone F: Hyperthermia inhibits cell proliferation and induces apoptosis: Relative signaling status of P53, S100A4, and Notch in heat sensitive and resistant cell lines. J Cell Biochem. 103:212–220. 2008.PubMed/NCBI View Article : Google Scholar
5	Yonezawa M, Otsuka T, Matsui N, Tsuji H, Kato KH, Moriyama A and Kato T: Hyperthermia induces apoptosis in malignant fibrous histiocytoma cells in vitro. Int J Cancer. 66:347–351. 1996.PubMed/NCBI View Article : Google Scholar
6	Kaczmarek A, Vandenabeele P and Krysko DV: Necroptosis: The release of damage-associated molecular patterns and its physiological relevance. Immunity. 38:209–223. 2013.PubMed/NCBI View Article : Google Scholar
7	Huang Y, Du S, Liu J, Huang W, Liu W, Zhang M, Li N, Wang R, Wu J, Chen W, et al: Diagnosis and prognosis of breast cancer by high-performance serum metabolic fingerprints. Proc Natl Acad Sci USA. 119(e2122245119)2022.PubMed/NCBI View Article : Google Scholar
8	Yin X, Yang J, Zhang M, Wang X, Xu W, Price CH, Huang L, Liu W, Su H, Wang W, et al: Serum metabolic fingerprints on bowl-shaped submicroreactor chip for chemotherapy monitoring. ACS Nano. 16:2852–2865. 2022.PubMed/NCBI View Article : Google Scholar
9	Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al: Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell. 149:1060–1072. 2012.PubMed/NCBI View Article : Google Scholar
10	Li YQ, Yang M and Li XT: Biochemical processes of ferroptosis and its roles in tumors. Chin J Bioche Mole Biol. 34:838–843. 2018.
11	Liu J and Liu WT: Research progress of ferroptosis in digestive system tumors. J Clin Exp Pathol. 38:331–333. 2022.
12	Zeng L, Liao Q, Zhao Q, Jiang S, Yang X, Tang H, He Q, Yang X, Fang S, He J, et al: Raltitrexed as a synergistic hyperthermia chemotherapy drug screened in patient-derived colorectal cancer organoids. Cancer Biol Med. 18:750–762. 2021.PubMed/NCBI View Article : Google Scholar
13	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev MoI Cell Biol. 15:178–196. 2014.PubMed/NCBI View Article : Google Scholar
14	Puisieux A, Brabletz T and Caramel J: Oncogenic roles of EMT inducing transcription factors. Nat Cell Biol. 16:488–494. 2014.PubMed/NCBI View Article : Google Scholar
15	Chen X and Li HL: Research progress in the mechanism of epithelial mesenchymal transformation of hepatocellular carcinoma cells. World Latest Med Information. 22:40–44. 2022.
16	Li D: Effect of intensity-modulated radiotherapy combined with local hyperthermia on mortalin expression and its relationship with cell proliferation and EMT in advanced liver cancer lesions. J Hainan Med Univ. 24:1842–1845. 2018.
17	Yang CX, Wei YH and Wei HF: Dihydroartemisinin inhibits growth and invasion of hepatoma cells by inhibiting expression of HMGB2 and reversing process of EMT. Chin J Immunol. 38:557–562. 2022.
18	Jia XB and Li Q: Research advances on deubiquitinating enzymes involved in the development of hepatocellular carcinoma. Chin J Clin Oncol. 47:260–264. 2020.
19	Vaupel P, Schmidberger H and Mayer A: The Warburg effect: Essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. 95:912–919. 2019.PubMed/NCBI View Article : Google Scholar
20	Ling S, Shan Q, Zhan Q, Ye Q, Liu P, Xu S, He X, Ma J, Xiang J, Jiang G, et al: USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation. Gut. 69:1322–1334. 2020.PubMed/NCBI View Article : Google Scholar
21	Wang FL and Hu J: Research progress on regulatorymechanism of ubiquitin modification on Warburg effect in malignant tumors. Cancer Res Prev Treat. 49:616–622. 2022.
22	Lei LM and Xu XL: Effect of intraoperative peritoneal washes on proliferation of gastric cancer cells in patients with stomach cancer. Oncol Progress. 18:1634–1636. 2020.
23	Chen J, Wang S and Xu H: Curative effect of radical gastrectomy combined with peritoneal lavage with thermal hypoosmotic solution in treatment of gastric cancer. Zhonghua Yi Xue Za Zhi. 81:730–732. 2001.PubMed/NCBI(In Chinese).
24	Peritoneal Tumor Committee of China Anti cancer association, Tumor Hyperthermia Committee of Guangdong Anti cancer association. Expert consensus on clinical application of intraperitoneal hyperthermic perfusion chemotherapy technology in China (version 2019). Chin Med J. 100:89–96. 2020.
25	Lu Y, Rivera-Rodriguez A, Tay ZW, Hensley D, Fung KLB, Colson C, Saayujya C, Huynh Q, Kabuli L, Fellows B, et al: Combining magnetic particle imaging and magnetic fluid hyperthermia for localized and image-guided treatment. Int J Hyperthermia. 37:141–154. 2020.PubMed/NCBI View Article : Google Scholar
26	Ding SW, Wu CW, Yu XG, Li H, Yu L, Zhang YX, Yang RP and Zhang W: Magnetic hydrogel with long in situ retention time for self-regulating temperature hyperthermia. Int J Hyperthermia. 38:13–21. 2021.PubMed/NCBI View Article : Google Scholar
27	Bottauscio O, Rubia-Rodríguez I, Arduino A, Zilberti L, Chiampi M and Ortega D: Heating of metallic biliary stents during magnetic hyperthermia of patients with pancreatic ductal adenocarcinoma: An in silico study. Int J Hyperthermia. 39:1222–1232. 2022.PubMed/NCBI View Article : Google Scholar
28	Shao N and Chen X: Research progress of superparamagnetic Fe3O4 nanoparticles in the treatment of malignant tumors. Oncol Progress. 20:1096–1098. 2022.
29	Kim H, Lee D, Kim J, Kim TI and Kim WJ: Photothermally triggered cytosolic drug delivery via endosome disruption using a functionalized reduced graphene oxide. ACS Nano. 7:6735–6746. 2013.PubMed/NCBI View Article : Google Scholar
30	Yang K, Zhang S, Zhang G, Sun X, Lee ST and Liu Z: Graphene in mice: Ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Lett. 10:3318–3323. 2010.PubMed/NCBI View Article : Google Scholar
31	Padhani AR and Ollivier L: The RECIST criteria: Implications for diagnostic radiologists. Br J Radiol. 74:983–986. 2001.PubMed/NCBI View Article : Google Scholar
32	Li HM, Jing XX and Liu YS: Effect of magnetic lipid microbubble-based gene vectors on human HepG2 cell growth. Chin J Mod Med. 29:16–20. 2019.
33	Enomoto A, Fukasawa T, Terunuma H, Nakagawa K, Yoshizaki A, Sato S and Miyagawa K: Decrease in MAP3Ks expression enhances the cell death caused by hyperthermia. Int J Hyperthermia. 39:200–208. 2022.PubMed/NCBI View Article : Google Scholar
34	Zhang N, Zhu H, Dong YH and Wang L: Establishment of an insufficient radiofrequency ablation orthotopic nude mouse model of hepatocellular carcinoma to study the invasiveness and metastatic potential of residual cancer. Oncol Lett. 18:2548–2553. 2019.PubMed/NCBI View Article : Google Scholar
35	Luo X, Ding G, Zheng X, Jin J, Liu Y, Zhang N, Wang J and Wang A: Improved mouse model of orthotopic transplantation for hepatocellular carcinoma. Chin J Comp Med. 31:16–22. 2021.
36	Xu J and Li X: Establishment of animal model of liver cancer. J Clin Hepatol. 8:116–118. 2005.
37	Gao CQ, Zhou XY and Liu JL: Research progress in mouse treatment model of liver cancer. Chin J Pathophysiol. 38:1686–1693. 2022.
38	Han PS, Yang L and Cui T: Establishment of the patient derived liver cancer xenograft model. Chin J Hepatobil Surg. 28:295–298. 2022.
39	Aboulkheyr Es H, Montazeri L, Aref AR, Vosough M and Baharvand H: Personalized cancer medicine: An organoid approach. Trends Biotechnol. 36:358–371. 2018.PubMed/NCBI View Article : Google Scholar
40	Kondo J and Inoue M: Application of cancer organoid model for drug screening and personalized therapy. Cells. 8(470)2019.PubMed/NCBI View Article : Google Scholar
41	Saltsman JA, Hammond WJ, Narayan NJC, Requena D, Gehart H, Lalazar G, LaQuaglia MP, Clevers H and Simon S: A human organoid model of aggressive hepatoblastoma for disease modeling and drug testing. Cancers (Basel). 12(2668)2020.PubMed/NCBI View Article : Google Scholar
42	Liu Q, Zhang Z, Liu Y, Cui Z, Zhang T, Li Z and Ma W: Cancer cells growing on perfused 3D collagen model produced higher reactive oxygen species level and were more resistant to cisplatin compared to the 2D model. J Appl Biomater Funct Mater. 16:144–150. 2018.PubMed/NCBI View Article : Google Scholar
43	Mittal R, Woo FW, Castro CS, Cohen MA, Karanxha J, Mittal J, Chhibber T and Jhaveri VM: Organ-on-chip models: Implications in drug discovery and clinical applications. J Cell Physiol. 234:8352–8380. 2019.PubMed/NCBI View Article : Google Scholar
44	Lin YZ, Wang JL, Ren HZ, et al: Research progress on organoids models of liver diseases. J Hepatopancreatobiliary Surg. 33:380–385. 2021.
45	Liao YL, Liu ZY and Wang H: Research progress on cultivation and application of liver cancer organoid. J Med Postgra. 35:664–667. 2022.
46	Zhao B: Application prospects of organoids in organ transplantation. Organ Transpl. 13:169–175. 2022.
47	Sampaziotis F, Justin AW, Tysoe OC, Sawiak S, Godfrey EM, Upponi SS, Gieseck RL III, de Brito MC, Berntsen NL, Gómez-Vázquez MJ, et al: Reconstruction of the mouse extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids. Nat Med. 23:954–963. 2017.PubMed/NCBI View Article : Google Scholar
48	Sampaziotis F, Muraro D, Tysoe OC, Sawiak S, Beach TE, Godfrey EM, Upponi SS, Brevini T, Wesley BT, Garcia-Bernardo J, et al: Cholangiocyte organoids can repair bile ducts after transplantation in the human liver. Science. 371:839–846. 2021.PubMed/NCBI View Article : Google Scholar